PTC Therapeutics’ Translarna NDA Withdrawn After FDA Cites Weak Data, Shares Drop 5%
PTC Therapeutics withdrew its New Drug Application for Translarna after FDA found its resubmission lacked substantial effectiveness data, halting development of its DMD treatment. Shares slumped over 5%, trading 10% below their 20-day average, while the SPDR S&P Biotech ETF holds a 1.29% weighting in the company.
1. NDA Withdrawal and FDA Feedback
PTC Therapeutics withdrew its NDA resubmission for Translarna after the FDA indicated the submitted data did not meet the agency’s threshold for substantial evidence of effectiveness. The therapy, designed to address nonsense mutation Duchenne muscular dystrophy, has been under development for over two decades.
2. Market Reaction and Technicals
PTC shares plunged 5.16% on the withdrawal, trading approximately 10% below their 20-day moving average and 11.5% below their 100-day average. The relative strength index around 34 suggests neutral momentum amid bearish MACD signals.
3. ETF Exposure Impact
The SPDR S&P Biotech ETF allocates 1.29% of its portfolio to PTC Therapeutics, making the company a minor contributor to the fund’s performance. The fund’s overall exposure to this setback remains limited given its diversified biotech holdings.